Strides Pharma Science shares gained 2.69% to ₹1,112.30 following the announcement of the strategic investment in its subsidiary Pivot Path Private Limited. The market response reflects investor confidence in the company's strategic divestment and the potential value unlock from this transaction. The stock movement demonstrates positive market sentiment toward the company's decision to monetize its stake while retaining strategic control.
Strides Pharma Science Limited has announced a strategic transaction involving its wholly owned subsidiary Pivot Path Private Limited, under which a consortium led by Ascent Capital Advisors India Pvt Ltd, along with co-investor Vintage Classic, will invest in the company. According to the company's exchange filing, the transaction values Pivot Path at approximately ₹2,300 million (~₹230 crore) on a post-money basis, representing a significant valuation for the technology-enabled platform. The board of directors approved this strategic investment at their meeting held on June 27, 2026. As per Business Standard, the transaction will allow the Bengaluru-based drugmaker to realise about ₹1 billion while retaining an approximately 20% stake in the company.
As part of the transaction, Strides Pharma Science will receive ₹75 crore at initial closing and an additional ₹25 crore on the first anniversary of closing, totaling ₹100 crore. The company will retain approximately 19.95% stake in Pivot Path, while investors will hold 65.05% with an ESOP Pool holding 15%. The company will also receive a primary capital infusion of ₹500 million (~₹50 crore) into the business to support its growth and technology development initiatives. Following completion of the transaction, Pivot Path will be reclassified as an associate of Strides Pharma Science, providing strategic flexibility for future partnerships. The valuation was based on an independent assessment carried out by a Securities and Exchange Board of India (Sebi)-registered merchant banker.
Pivot Path was carved out from Arco Lab Private Limited, Strides' Global Capability Centre, pursuant to a Scheme of Arrangement approved by the National Company Law Tribunal (NCLT) in May 2026. The platform has been built as a technology-enabled offering providing life sciences consulting, digital transformation, quality and compliance, and technology-enabled operational services. For FY26, the carved-out business reported revenue of ₹1,447 million and EBITDA of ₹169 million, as per the press release. The business evolved into an independent platform serving industry-leading customers as demand from external pharmaceutical and life sciences companies grew. To support its next phase of growth, serve global customers effectively, build agentic-AI platforms, and enable access to external capital, the business was carved out into Pivot Path.
Pivot Path focuses on delivering consulting, digital innovation, compliance, and operational services for pharmaceutical and manufacturing companies. As per Badree Komandur, MD & Group CEO of Strides, "Pivot Path exemplifies Strides proven capability to identify, incubate and scale high-potential businesses. Over the past years, we have built a platform with specialised capabilities, a growing customer base and a strong foundation for future growth. As the business enters its next phase, we believe this is the right time to bring in a strategic investment partner with the expertise and capital to accelerate its growth." The investment is intended to support Pivot Path's next phase of growth while enabling the parent company to unlock value from the business and continue participating in its future growth. Ascent Capital Managing Director & Founder Raja Kumar noted that as an independent entity, Pivot Path is well-positioned to combine technology and Agentic-AI with its 400-plus subject matter experts to build purpose-built solutions for global customers. Ascent Capital expects Pivot Path to expand its presence in the global life sciences sector by combining its domain expertise with AI-driven and technology-enabled solutions.
